Potential Therapies for the HIV-Associated Lipodystrophy Syndrome
The HIV associated liposdystrophy syndrome consists of four parts that are likely to be related, but that appear to be able to exist independently in an HIV-infected individual (1, 2, 3, 4, 5, 6). These four components include: fat deposition (buffalo hump, visceral fat, breast enlargement), subcutaneous fat atrophy, disorders of glucose and insulin metabolism, most commonly manifest as glucose intolerance, and disorders of lipid and cholesterol metabolism, with elevations in total cholesterol, fasting triglycerides, and low density lipoprotein cholesterol (non-HDL cholesterol). The epidemiology and potential mechanisms for these are discussed in detail in other chapters in this book. It is clear that both of the body shape abnormalities are distressing to patients, and have lead to refusal to initiate anti-retroviral therapy or termination of ART by patients. In non-HIV-infected patients, visceral fat has a strong association with glucose intolerance and adverse cardiovascular events (7). In population studies, elevations in cholesterol and triglycerides and glucose intolerance/insulin resistance are associated with adverse outcomes as well (8, 9, 10, 11, 12). No definitive studies exist yet for HIV to assure us that the same ourcomes will occur with these metabolic abnormalities in the HIV infected patient, but there is sufficient concern that these association will hold, that interventions to attempt to control these metebolic abnormalities are being investigated.
KeywordsRecombinant Human Growth Hormone Protease Inhibitor Therapy Lipodystrophy Syndrome Buffalo Hump Body Shape Change
Unable to display preview. Download preview PDF.
- 13.Lichtenstein K, Ward D, Delaney K, Moorman A, Palella F, Young B, Wood K, Holmberg S. Clinical factors related to the severity of fat redistribution in the HIV outpatient study. 7th CROI, San Francisco, CA 2000.Google Scholar
- 15.Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. NEJM 1988; 319: 173–179.CrossRefGoogle Scholar
- 23.Engelson ES, Glesby M, Shikan J et al. Effest of recombinant human growth hormone on the treatment of visceral fat accumulation in HIV infection: J AIDS 2002; 30: 379–391.Google Scholar
- 27.Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity Relat Metab Disord 1992; 16: 991–997.Google Scholar
- 28.Dieterich D, Aymat R, Braun J, Mullen M, McMeeking A, Weisz K, Kreiswirth K, O’Brien K, Lawson, Hergenroeder P, Tirelli R. Incidence of body habitus changes in a cohort of 725 HIV-infected patients. 6th CROI, Chicago, Illinois 1999.Google Scholar
- 29.Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals Internal Med 2000; 133: 263–274.Google Scholar
- 36.Dube MP, Sprecher D, Henry WK, Aberg JA, Torrinani FJ, Hodis HN, Scouten J, Levin J, Myers G, Zachin R, Nevin T, Currier JS. Preliminary Guidelines for he evaluation and management of dyslipidemia in adults infected with the human immunodeficiency virus and receiving antiretroviral therapy. Clinical Infectious Disease 2000; 31: 1216–1224.CrossRefGoogle Scholar
- 39.Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquired Immune Deficiency Syndrome 2000; 23: 35–43.Google Scholar
- 41.Murphy R, Brun S, King M, et al. Kaletra in ART naïve subjects: 4 year follow up study M97-720. Abstract H-165,42nd ICAAC, San Diego, California, 2002.Google Scholar